Clinical Trial Update: Neoadjuvant SBRT Followed by Sintilimab Plus Chemotherapy for N3-Positive NSCLC [Phase 2]

View source ↗

Summary

This is a Phase 2 neoadjuvant trial of SBRT followed by sintilimab plus chemotherapy for N3-positive locally advanced non-small cell lung cancer, and it is curr…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer
• Stage Iiib Non-small Cell Lung Cancer
• Stage Iiic Non-small Cell Lung Cancer

Drugs mentioned

• Sintilimab (Tyvyt) (sintilimab)

Snippet

Sponsor: Yang Hong | Conditions: Locally Advanced Non-Small Cell Lung Cancer, Stage IIIb Non-small Cell Lung Cancer | Phase 2 | Status: NOT_YET_RECRUITING